Introduction: Data on prophylactic cranial irradiation (PCI) after complete resection of SCLC are limited. The purpose of this study was to investigate the impact of PCI in this population.
Introduction
Lung cancer is the most frequently diagnosed cancer and the leading cause of cancer-related deaths worldwide. 1 SCLC accounts for approximately 15% of all lung cancers and is characterized by rapid doubling time and early development of distant metastases. 2 Even though SCLC is highly sensitive to chemotherapy and radiation therapy, the prognosis of most patients with this disease has remained poor over the past several decades owing to the rapid development of chemoresistance. 3 The blood-brain barrier restricts the penetration of chemotherapeutic agents into the brain, and as a result, brain metastasis (BM) is one of the main types of relapse, occurring in more than 50% of patients. 4 The first clinical trial to evaluate the role of prophylactic cranial irradiation (PCI) in patients with SCLC was conducted in the 1970s, and it demonstrated a significant reduction in BM. 5 Subsequent clinical trials established PCI as a standard therapy for both extensive SCLC and limited SCLC with good responses to first-line treatment. [6] [7] [8] [9] [10] [11] [12] According to a previous study, surgical resection in selected patients with early-stage SCLC, especially stage I, had favorable results. 13 Currently, the recommendation of PCI for patients with a completely resected SCLC is based on data from trials evaluating the impact of PCI on patients without surgery. In the present study, we have summarized the clinical data of patients with completely resected SCLC in our institution to evaluate the role of PCI in this population.
Material and Methods

Patients
This study was approved by the Institutional Review Board of Shanghai Chest Hospital (Shanghai, People's Republic of China). All of the patients had SCLC that was diagnosed at this hospital between January 2006 and January 2014. SCLC staging was performed according to the seventh tumor node metastasis (TNM) classification. 14, 15 The inclusion criteria were as follows: (1) patients with primary nonmetastatic SCLC and (2) patients who underwent surgical resection as initial treatment for primary tumor. The baseline clinical characteristics included age at diagnosis, tumor histologic type, extent of lymph nodes involved, histologic grade, presence or absence of primary radiotherapy, presence or absence of chemotherapy, performance status, smoking history, and sex. Patients who had microscopically positive (R1) or macroscopically positive (R2) resections and those without survival and therapy details were excluded from the analysis. Overall survival (OS) was defined as the date of diagnosis until the date of death or last follow-up visit.
Statistical Methods
For descriptive purposes, demographic and clinical data were summarized as medians with ranges for continuous variables and categorical variables were summarized by means of absolute and percentage numbers. Baseline characteristics were compared between the PCItreated and non-PCI-treated cohorts by using the chisquare test for categorical data. Survival results were summarized as median values and two-sided 95% confidence intervals (CIs) and analyzed by the Kaplan-Meier method. Hazard ratios (HRs) and 95% CIs were calculated using Cox's proportional hazard model. The cumulative incidence of BM was estimated by the Kaplan-Meier method, and groups were compared by using the log-rank test. Statistical significance was defined as a p value less than 0.05. SPSS statistical software, version 22 (IBM Corp., Armonk, NY), was used for all statistical analyses.
Results
A total of 349 patients (115 patients who received PCI therapy [the PCI-treated cohort] and 234 patients who did not [the non-PCI-treated cohort]) were included in the study (Fig. 1) . The demographic data of all patients are shown in (Fig. 2) .
Multivariate Analysis
On multivariate analysis, OS was significantly longer in patients with p-stage I disease. Female sex was associated with improved survival. Multivariate analysis also demonstrated that adjuvant chemotherapy and postoperative radiotherapy to the lung were independent prognostic factors for OS. Smoking and increased tumor size were associated with worse survival (Table 2) .
Cerebral Recurrence
During the observation period, BM developed in 13.0% of patients (15 of 115) in the PCI-treated cohort and 22.6% of patients (53 of 234) in the non-PCI-treated cohort. Curves for the cumulative occurrence of BM are shown in Figure 3 . Among stage III patients, BM developed in 14.0% (eight of 57) in the PCI-treated cohort and 27.8% (30 of 108) in the non-PCI-treated group. There was a significantly higher risk for cerebral recurrence from the time of diagnosis in the non-PCI-treated cohort (p ¼ 0.018). Among patients with p-stage I disease, BM developed in 13.6% (eight of 59) in the non-PCI-treated cohort and 10.5% (two of 19) in the PCI-treated cohort. In patients with p-stage II disease, BM developed in 22.4% (15 of 67) in the non-PCI-treated cohort and 12.8% (five of 39) in the PCI-treated cohort. However, there was no significant difference in the risk for cerebral recurrence between the two cohorts with regard to the time to recurrence among p-stage I (p ¼ 0.389) and II (p ¼ 0.094) patients (Fig. 3) .
Discussion
In 1999, a meta-analysis analyzed individual data of 987 patients with SCLC in complete remission who took part in seven trials that compared PCI with no PCI. The combined results revealed a significant (p ¼ 0.01) survival benefit in the PCI group as compared with in the control group, with a pooled relative risk of 0.84 and a significantly decreased cumulative incidence of BM (relative risk 0.46, p < 0.001). 9 The current guideline recommends PCI therapy for patients with good responses (complete response and partial response) to first-line treatment to reduce the incidence of BM and increase OS. 16 In the present study, we addressed whether PCI therapy provide benefits for those with completely resected SCLC. The results demonstrated a significant difference in BM occurrence and OS between patients with and without PCI therapy. Our results are consistent with those of a previous study, in which the clinical data of 67 patients in the PCItreated cohort and 126 patients in the non-PCI-treated cohort were collected. The results demonstrated that receipt of PCI therapy was an independent significant predictor of improved survival for patients with completely resected SCLC (HR ¼ 2.339, p ¼ 0.001). 17 Further subgroup analysis in the present study showed that the OS benefits of PCI therapy were significant in patients with stage II or III disease; however, the difference was not statistically significant among those with stage I disease. Recently, a retrospective study summarized clinical data of patients in the National Cancer Data Base who had pathologic T1-2N0M0 SCLC and underwent complete resection; the results demonstrated that treatment with adjuvant chemotherapy and radiation directed at the brain was associated with improved survival when compared with no adjuvant therapy (HR ¼ 0.52, 95% CI: 0.36-0.75). However, subgroup analyses showed no difference between the group of patients who received PCI to the brain after surgery and the surgery-alone group (HR ¼ 1.46; 95% CI: 0.46-4.64). 18 Similarly, another study demonstrated that among patients with p-stage I disease, the difference between the 2-year and 5-year OS rates for patients in the PCI and non-PCI groups was not significant (100% versus 58.3% and 87.1% versus 74.4%, respectively; p ¼ 0.601). 17 The different survival benefits of PCI therapy among patients with different stages of disease indicated that it might be a good choice for stage II/III patients with completely resected SCLC but not for stage I patients. This speculation was confirmed by subgroup analyses of the cumulative incidence of BM between the PCI-treated and non-PCI-treated cohorts. For patients with p-stage I disease, the difference in cumulative incidence of BM was not significant between the PCItreated and non-PCI-treated cohorts. Among stage II patients, unlike the significant difference in OS between the PCI-treated and non-PCI-treated cohorts, the difference in the cumulative incidence of BM between the two groups was not significant (p ¼ 0.094). However a clear separation of curves for the cumulative occurrence of BM was observed between the PCI-treated and non-PCItreated cohorts. The lack of a statistically significant difference might be caused by the relatively small sample size of stage II patients. Among patients with stage III disease, the cumulative incidence of BM in the non-PCItreated cohort was higher than that in the PCI-treated cohort.
It was reported that the lower incidence of BM in stage I patients might explain why PCI therapy failed to be efficacious in this population. 19 Similarly, the high frequency of BM in surgically resected patients with pstage II/III SCLC might explain the superior survival benefits of PCI therapy in this population. 20 Previously, a multi-institutional prospective study (JCOG9101) reported that the incidence of BM was 15% (nine of 61) in patients with surgically resected SCLC and only 11% (four of 35) in patients with p-stage I disease, but it was 19.2% in patients with p-stage II/III disease. 21 Similar results were also achieved in a retrospective study that evaluated the factors affecting the risk for BM in patients with SCLC with surgery. The results showed that the rates of BM in patients with p-stages I, II, and III were 6.25% (two of 32), 28.2% (11 of 39), and 29.1% (16 of 55), respectively, indicating a higher incidence of BM in stage II/III disease and a low incidence in stage I disease. 22 Similarly, in the present study, among the non-PCI-treated cohort, the rates of BM in patients with p-stage I, II, and III disease were 13.6% (eight of 59), 22 .4% (15 of 67), and 27.8% (30 of 108), respectively. Considering the higher incidence of BM in surgically resected stage II/III SCLC subgroups, PCI might play an important role in this population.
The conclusions of this study should be interpreted while keeping in mind its retrospective nature. Treatment selection biases could have been introduced, which would affect the conclusions. In addition, the small sample size in each subgroup might have affected the statistical analysis. Moreover, because of the limitation of the database, we could not collect data on toxicity from PCI therapy in most patients, so we were not able to evaluate the adverse effects that may result from PCI therapy.
In conclusion, the data presented in the current study support the role of PCI in patients with completely resected SCLC, as it was associated with a significant survival advantage. However, subgroup analyses demonstrated that the OS benefits of PCI therapy were significant in patients with stage II/III disease but not in patients with stage I disease. A relatively lower incidence of BM in stage I patients might explain the inferior efficacy of PCI for this population.
